Comparative Pharmacology
Head-to-head clinical analysis: NORPACE CR versus QUINACT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORPACE CR versus QUINACT.
NORPACE CR vs QUINACT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ia antiarrhythmic agent; decreases myocardial excitability and conduction velocity, and prolongs refractory period by blocking sodium channels.
Quinacrine is a 9-aminoacridine derivative that intercalates into DNA, inhibiting DNA replication and transcription, and also has antimalarial, anti-inflammatory, and antihelminthic properties. It inhibits phospholipase A2 and suppresses immune responses.
Disopyramide controlled-release: 200 mg orally every 12 hours; maximum 400 mg/day.
100 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life: 6-12 hours (normal renal function); prolonged to 12-20 hours in renal impairment. In coronary artery disease, half-life may be extended due to reduced clearance.
Terminal elimination half-life: 12-15 hours (prolonged in renal impairment; CrCl <30 mL/min: 24-40 hours)
Renal (50-57% unchanged), hepatic metabolism (30-40%), fecal (<10%). Dose adjustment required for CrCl <40 mL/min.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)